NCT06669234

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

A Phase 1, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ALN-F1202, an siRNA Against Factor XII, in Healthy Adults

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Regeneron Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This clinical research trial will evaluate the safety and tolerability of an experimental drug, ALN-F1202, in healthy participants. The purpose of this trial is to learn about how safe and tolerable the experimental drug is. The trial is looking at several other research questions, including: * What side effects may happen from taking the experimental drug? * How much experimental drug is in the blood at different times? * Whether the body makes antibodies against the experimental drug (which could make the drug less effective or could lead to side effects). * What is the best dose of the experimental drug?

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	ALN-F1202	Administered per the protocol
DRUG	Matching Placebo	Administered per the protocol

Timeline

• Start date: 2025-03-06
• Primary completion: 2026-07-30
• Completion: 2026-07-30
• First posted: 2024-11-01
• Last updated: 2026-02-23

Locations

1 site across 1 country: Belgium

Regulatory

• FDA-regulated drug study